Insights into the roles of hnRNP A2/B1 and AXL in non‑small cell lung cancer

Oncology Letters

Volumn 10, Issue 3, 2015, Pages 1677-1685

  Qu, Xiao Han ^a   Liu, Jin Lu ^a   Zhong, Xin Wen ^a   Li, Xi ^a   Zhang, Qi Gang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

AXL receptor tyrosine kinase; Heterogeneous nuclear ribonucleoprotein A2 B1; Non small cell lung cancer

Indexed keywords

AXL PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2 B1; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; RISK FACTOR; RNA INTERFERENCE; SURVIVAL; TISSUE MICROARRAY;

EID: 84937439419     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3457     Document Type: Article

References (27)

1. SiegelR, NaishadhamD and JemalA: Cancer statistics, 2013. CA Cancer J Clin63: 11-30, 2013.
2. Yang Y, Li H, Hou S, HuB, LiuJ and WangJ: The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One8: e65309, 2013.
3. Grutters JP, Kessels AG, Pijls-JohannesmaM, DeRuysscherD, JooreMA and LambinP: Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A meta-analysis. Radiother Oncol95: 32-40, 2010.
4. Vansteenkiste J, Crinò L, Dooms C, DouillardJY, Faivre-FinnC, LimE, RoccoG, SenanS, Van SchilP, VeronesiG, etal; Panel Members: 2nd ESMO Consensus Conference on Lung Cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol25:1462-1474, 2014.
5. HanSP, TangYH and SmithR: Functional diversity of the hnRNPs: Past, present and perspectives. BiochemJ430: 379-392, 2010.
6. Majumder M, Yaman I, Gaccioli F, ZeenkoVV, WangC, CapraraMG, VenemaRC, KomarAA, SniderMD and HatzoglouM: The hnRNA-binding proteins hnRNP L and PTB are required for efficient translation of the Cat-1 arginine/lysine transporter mRNA during amino acid starvation. Mol Cell Biol29: 2899-2912, 2009.
7. Hutchison S, LeBel C, Blanchette M and Chabot B: Distinct sets of adjacent heterogeneous nuclear ribonucleoprotein (hnRNP) A1/A2 binding sites control 5' splice site selection in the hnRNP A1 mRNA precursor. JBiol Chem277: 29745-29752, 2002.
8. Han K, Yeo G, An P, BurgeCB and GrabowskiPJ: A combinatorial code for splicing silencing: UAGG and GGGG motifs. PLoS Biol3: e158, 2005.
9. Dreyfuss G, Kim VN and Kataoka N: Messenger-RNA-binding proteins and the messages they carry. Nat Rev Mol Cell Biol3: 195-205, 2002.
10. Chettouh H, Fartoux L, Aoudjehane L, WendumD, ClapéronA, ChrétienY, ReyC, ScattonO, SoubraneO, ContiF, etal: Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors. Cancer Res73: 3974-3986, 2013.
11. Chen Z-Y, Cai L, Zhu J, ChenM, ChenJ, LiZH, LiuXD, WangSG, BieP, JiangP, etal: Fyn requires HnRNPA2B1 and Sam68 to synergistically regulate apoptosis in pancreatic cancer. Carcinogenesis32: 1419-1426, 2011.
12. Golan-Gerstl R, Cohen M, ShiloA, SuhSS, BakàcsA, CoppolaL and KarniR: Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res71: 4464-4472, 2011.
13. Santarosa M, Del Col L, Viel A, BiviN, D'AmbrosioC, ScaloniA, TellG and MaestroR: BRCA1 modulates the expression of hnRNPA2B1 and KHSRP. Cell Cycle9: 4666-4673, 2010.
14. He Y, Brown MA, Rothnagel JA, SaundersNA and SmithR: Roles of heterogeneous nuclear ribonucleoproteinsA andB in cell proliferation. JCell Sci118: 3173-3183, 2005.
15. Tauler J, Zudaire E, Liu H, ShihJ and MulshineJL: hnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines. Cancer Res70: 7137-7147, 2010.
16. Katsimpoula S, Patrinou-GeorgoulaM, MakriliaN, DimakouK, GuialisA, OrfanidouD and SyrigosKN: Overexpression of hnRNPA2/B1 in bronchoscopic specimens: A potential early detection marker in lung cancer. Anticancer Res29: 1373-1382, 2009.
17. Fielding P, Turnbull L, PrimeW, WalshawM and FieldJK: Heterogeneous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens: A clinical marker of early lung cancer detection. Clinical Cancer Res5: 4048-4052, 1999.
18. KorshunovVA: Axl-dependent signalling: A clinical update. Clin Sci (Lond) 122: 361-368, 2012.
19. Rothlin CV, LeightonJA and GhoshS: Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer. Inflamm Bowel Dis20: 1472-1480, 2014.
20. Wu H, Tang H, Chen Y, Wang H and Han D: High incidence of distal vaginal atresia in mice lacking Tyro3 RTK subfamily. Molecular reproduction and development 75: 1775-1782, 2008.
21. Wang H, Chen SU, ChenY, WangH, WuH, TangH, XiongW, MaJ, GeY, LuQ and HanD: The role of Tyro3 subfamily receptors in the regulation of hemostasis and megakaryocytopoiesis. Haematologica92: 643-650, 2007.
22. Mudduluru G, Ceppi P, KumarswamyR, ScagliottiGV, PapottiM and AllgayerH: Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene30: 2888-2899, 2011.
23. He Y, Rothnagel JA, Epis MR, LeedmanPJ and SmithR: Downstream targets of heterogeneous nuclear ribonucleoprotein A2 mediate cell proliferation. Mol Carcinog48: 167-179, 2009.
24. Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol17: 1471-1474, 2010.
25. Man YG, Martinez A, AvisIM, Hong SH, CuttittaF, VenzonDJ and MulshineJL: Phenotypically different cells with heterogeneous nuclear ribonucleoprotein A2/B1 overexpression show similar genetic alterations. Am J Respir Cell Mol Biol23: 636-645, 2000.
26. Linger RM, Cohen RA, CummingsCT, SatherS, Migdall-WilsonJ, MiddletonDH, LuX, BarónAE, FranklinWA, MerrickDT, etal: Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene32: 3420-3431, 2013.
27. Zhang Z, Lee JC, Lin L, OlivasV, AuV, LaFramboiseT, Abdel-RahmanM, WangX, LevineAD, Rho JK, etal: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet44: 852-860, 2012.